论文部分内容阅读
AIM:To explore the effects of curcumin(CMN)on hepatic injury induced by acetaminophen(APAP)in vivo.METHODS:Male mice were randomly divided into three groups:groupⅠ(control)mice received the equivalent volumes of phosphate-buffered saline(PBS)intraperitoneally(ip);GroupⅡ[APAP+carboxymethylcellulose(CMC)]mice received 1%CMC(vehicle)2h before APAP injection;GroupⅢ(APAP+CMN)mice received curcumin(10 or 20 mg/kg,ip)2 h before before or after APAP challenge.In GroupsⅡandⅢ,APAP was dissolved in pyrogen-free PBS and injected at a single dose of 300 mg/kg.CMN was dissolved in 1%CMC.Mice were sacrificed 16 h after the APAP injection to determine alanine aminotransferase(ALT)levels in serum and malondialdehyde(MDA)accumulation,superoxide dismutase(SOD)activity and hepatocyte apoptosis in liver tissues.RESULTS:Both pre-and post-treatment with curcumin resulted in a significant decrease in serum ALT compared with APAP treatment group(10 mg/kg:801.46±661.34 U/L;20 mg/kg:99.68±86.48 U/L vs 5406.80±1785.75 U/L,P<0.001,respectively).The incidence of liver necrosis was significantly lowered in CMN treated animals.MDA contents were significantly reduced in 20 mg/kg CMN pretreatment group,but increased in APAP treated group(10.96±0.87 nmol/mg protein vs 16.03±2.58 nmol/mg protein,P<0.05).The decrease of SOD activity in APAP treatment group and the increase of SOD in 20 mg/kg CMN pretreatment group were also detected(24.54±4.95 U/mg protein vs 50.21±1.93 U/mg protein,P<0.05).Furthermore,CMN treatment efficiently protected against APAPinduced apoptosis via increasing Bcl-2/Bax ratio.CONCLUSION:CMN has significant therapeutic potential in both APAP-induced hepatotoxicity and other types of liver diseases.
AIM: To explore the effects of curcumin (CMN) on hepatic injury induced by acetaminophen (APAP) in vivo. METHODS: Male mice were randomly divided into three groups: group I (control) mice received the equivalent volumes of phosphate- buffered saline Group Ⅱ [APAP + carboxymethylcellulose (CMC)] mice received 1% CMC (vehicle) 2h before APAP injection; Group Ⅲ (APAP + CMN) mice received curcumin (10 or 20 mg / kg, ip) before or after APAP challenge.In Groups II and III, APAP was dissolved in pyrogen-free PBS and injected at a single dose of 300 mg / kg. CMC was dissolved in 1% CMC. Microparticles were sacrificed 16 h after the APAP injection to determine alanine aminotransferase (ALT) levels in serum and malondialdehyde (MDA) accumulation, superoxide dismutase (SOD) activity and hepatocyte apoptosis in liver tissues. Both outcomes: Both pre-and post-treatment with curcumin resulted in a significant decrease in serum ALT compared with APAP treatment group (10 mg / kg: 801.46 ± 661.34 U / L; 20 mg / kg: 99.68 ± 86.48 U / L v s 5406.80 ± 1785.75 U / L, P <0.001, respectively). The incidence of liver necrosis was significantly lowered in CMN treated animals. MDDA contents were significantly reduced in 20 mg / kg CMN pretreatment group, but increased in APAP treated group (10.96 ± 0.87 nmol / mg protein vs 16.03 ± 2.58 nmol / mg protein, P <0.05). The decrease of SOD activity in APAP treatment group and the increase of SOD in 20 mg / kg CMN pretreatment group were also detected (24.54 ± 4.95 U / mg protein vs 50.21 ± 1.93 U / mg protein, P <0.05) .Furthermore, CMN treatment efficiently protected against APAP induced apoptosis via increasing Bcl-2 / Bax ratio.CONCLUSION: CMN has significant therapeutic potential in both APAP-induced hepatotoxicity and other types of liver diseases.